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VTE Prophylaxis in Cesarean 
Section
Frederico José Amédeé Péret and Liv Braga de Paula
Abstract
Venous thromboembolism (VT is a major cause of maternal mortality and severe 
morbidity. Pharmacological and non-pharmacological methods of prophylaxis are 
therefore often used for women considered to be a risk including women who have 
given birth by cesarean section. The risk is potentially increased in women with a 
personal or family history of VTE, women with genetic or acquired thrombophilia, 
and another risk factors like sickle cell disease, inflammatory bowel disease, active 
cancer, obesity, preeclampsia·and SARS COVID 19 infection. However, a specific 
score in obstetrics has not yet been well defined. Recommendations from major 
society guidelines for post-cesarean section (C/S) thromboprophylaxis differ 
greatly; the safety and efficacy of drug prophylaxis - mainly low molecular weight 
heparins - has been demonstrated, but large scale randomized trials of currently-
used interventions should be conducted. The purpose of this chapter is to discuss 
the indications and contraindications for VTE prophylaxis in cesarean sections, 
prophylaxis regimens and potential adverse events.
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1. Introduction
Venous thromboembolism (VTE) is a major cause of maternal morbidity and 
mortality. The risk of VTE is particularly elevated during the postpartum period 
and especially after cesarean section (CS) delivery. The risk of VTE was fourfold 
greater following CS than following vaginal delivery; seemed independent of other 
VTE risk factors; and was greater following emergency CS than following elective 
procedures [1].
Although a number of risk factors have been identified, the size of the increases 
in risk attributable to these factors is generally poorly quantified and there is 
considerable variation in the approach to prophylaxis of venous thromboembolism 
after CS [2–5].
In women with risk factors a combination of pharmacological and non- 
pharmacological methods are recommended. There is limited literature on the 
effect of mechanical methods for postpartum thromboprophylaxis, however 
benefit has been shown in other clinical areas [2, 4].
Antithrombotic prophylaxis are based on unfractionated heparin (UFH), low-
molecular weight heparin (LMWH). LMWH was associated with fewer adverse 
effects when compared with UFH. Therefore, LMWH is considered to be a safe and 
effective in for postpartum thromboprophylaxis, although high-quality evidence is 
not available [1, 2].
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In this chapter we will discuss the risk factors for VTE, their interactions and 
potential risk scores, as well as the prophylaxis alternatives and international 
guidelines for the prevention of VTE.
2. Epidemiology of VTE in pregnancy and puerperium
Women during pregnancy and the immediate puerperal period are considered 
at risk for VTE and there is a substantially higher prevalence that in non-pregnant 
women of the same age. A case-control study reported that compared with non-
pregnant women, the risk of VTE was increased five-fold during pregnancy, and by 
60-fold during the first three months after birth. However the absolute risk remains 
low, estimated at around one to two in 1000 pregnancies [6, 7].
The incidence of VTE, especially Pulmonary Embolism (PE), is believed to 
be much higher during the immediate puerperal period - mostly associated with 
cesarean section - with between 40% and 60% of all acute PE cases reported 
to occur postpartum(with a estimated 15-fold increased risk of PE postpartum 
compared with during pregnancy). In a systematic review the risk of VTE was 
fourfold greater following CS than following uncomplicated vaginal delivery; and 
was greater following emergency CS than following elective CS. On average, was 
estimated that three in 1,000 women will develop a VTE following CS [6, 7].
However a decline overall in deaths associated with VTE in recent years has 
been observed since publication and more adherence to prevention guidelines for 
obstetric population [2, 6].
Currently there one reported study on incidence of Deep venous thrombosis 
(DVT) in women receiving thromboprophylaxis using heparin after CS. This study 
found that the incidence of asymptomatic DVT among women at high risk of VTE 
was 3.9%. In patients without thromboprophylaxis symptomatic DVT was detected 
in 0.04% and 0.5% [7–9].
3. Risk factors for VTE in pregnancy and puerperium
Some groups of women have a higher risk of developing VTE. The most 
important individual risk factor for VTE in pregnancy is a personal history of 
thrombosis without a trigger factor and/or following use of estrogen-based 
hormonal therapy. For women who have had a previous thrombosis in pregnancy, 
the risk of VTE increases considerably in subsequent pregnancies if antenatal 
thromboprophylaxis is not used, with an estimated increased risk of recurrence of 
three- to four-fold [1–4].
Another important individual risk factor for VTE in pregnancy is the presence 
of an inherited or acquired thrombophilia (a condition that predisposes individuals 
to developing thromboses) [2–4].
The risk of a thromboembolic event occurring during pregnancy has been 
shown to differ according to the nature of the thrombophilia, with estimates of risk 
varying from 5–33% (Homozygotic mutations or multiple thrombophilias) [3, 7, 8].
Other pregnancy-related factors shown to increase the risk of VTE include 
multiple gestation, pregnancy induced hypertension, prolonged active fase of 
labour and cesarean section (mainly in the emergency and or after labor). In a case–
control study the overall risk of VTE was 0.09%, with a higher risk of events in the 
postnatal period following cesarean birth; and the authors verified that the risk in 
the antenatal period was estimated as 0.18% following cesarean section compared 
with 0.03% without cesarean section [2, 6, 7].
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Obesity, smoking, advanced maternal age, severe heart disease, sickle cell 
disease, inflammatory bowel disease, active cancer, family history of VTE, and 
prolonged immobilization are other commonly reported risk factors [2].
VTE risk factors vary in their association with but appear to be common. In a 
recently published cross-sectional study of prospectively collected data from 21 
019 sequential postpartum VTE risk assessments in a hospital setting the most 
prevalent VTE risk factors related to maternal and delivery characteristics included 
overweight and obesity (36%), age ≥ 35 (35%) and cesarean section (32%). Over 
three-quarters of women had at least 1 VTE risk factor (78%), and over 40% had 
multiple (2 or more) VTE risk factors. An important finding is the fact that in 19% 
of women all VTE risk developed during delivery or in the post-partum period (and 
were not present prior to the peripartum period) highlighting the critical impor-
tance of performing continuos VTE risk assessment even after delivery [8, 9].
COVID-19 is new disease with potentially impact in pregnancy and pueperium. 
The evidence addressing the issues of coagulopathy and thrombosis in pregnancy 
in association with COVID-19 is sparse and so far, there is no available high-quality 
studies at this moment. However, given the possible association between the hyper-
coagulability characteristic of pregnancy and the risk increase in COVID-19-related 
VTE, the International Society of Thrombosis and Haemostasys (ISTH), as well as 
the Ministry of Health in Brazil, suggest that all pregnant and postpartum women 
admit had at the hospital for COVID-19 (i.e., severe and moderate cases) receiving 
pharmacological prophylaxis [10, 11].
4. Interaction of VTE risk factors and potencial risk scores
The interaction of VTE risk factors remains an important knowledge gap. 
However in a large hospital- based case–control study, including 559 women with 
objectively verified VTE during pregnancy or the postpartum period and 1229 
controls, some risk factors exhibited additive interaction (as observed with the 
combination of assisted reproductive technology with multiple pregnancy, and 
emergency cesarean section with infection), while others appeared to act as mul-
tipliers, as with the combination of antepartum immobilization and elevated body 
mass index [12, 13].
In particular, understanding how these VTE risk factors translate into absolute 
PA-VTE is essential. A risk prediction model for postpartum VTE was recently 
developed using large data on 433 353 deliveries. This model was externally vali- 
dated using another data sets of 662 387 deliveries. Emergency cesarean section, 
stillbirth, varicose veins, preeclampsia/eclampsia, infection, and medical comor-
bidities were the strongest VTE predictors in the final multivariable model. The risk 
prediction model was able to discriminate postpartum women with and without 
VTE with statistical significance [C statistic of 0.70 (95% CI, 0.67-0.73)] [13].
The risk assessment models in surgical patients (e.g., Caprini and Padua) to 
predict VTE after cesarean delivery has not been adequately studied suggesting the 
establishment of a maternal clinical registry and more extensive research to identify 
optimal models with which to predict VTE risk in the obstetrical population [4, 13].
At the Maternity Hospital of the Hospital das Clínicas, Universidade de São 
Paulo in Brazil – a tertiary referral service provider for obstetric pathologies - a 
risk score for VTE was developed since 2014. Since the establishment of this risk 
score, there have been no more maternal deaths from PE during hospitalization or 
up to three months postpartum. Among patients who received prophylaxis with 
enoxaparin, 0.4% had VTE (failure of treatment); in the untreated (that is, low 
risk) group had 0.06% of VTE. In our institution we have adapted this score since 
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2020 and The National Specialized Commission on Thromboembolism of the 
Febrasgo (CNE-TEV), based on this national experience proposes the risk score for 
pregnant women and hospitalized mothers in Brazil. The risk factors were divided 
into high, medium and low risks, which score, respectively, 3, 2 or 1 point. The fine 
score occurs by the sum of the values attributed to each factor present in the patient. 
Pharmacological anticoagulation with is indicated for patients with a score risk of 
VTE greater than or equal to three [14, 15].
The score is summarized in Table 1.
5. Considerations for VTE prophylaxis in cesarean section
A Cochrane’s systematic review concluded that there is insufficient evidence 
of post-cesarean thromboprophylaxis due to the small number of studies and 
different comparison criteria. Although the risk of VTE associated with cesarean 
section is low, when there is a relationship with other risk factors, the occurrence 
of VTE becomes significant and the institution of thromboprophylaxis should be 
indicated [1, 2].
Based on observational data, some authors have attempted to calculate the 
number needed to treat (NNT) to prevent 1 episode of VTE during the postpartum 
period, and reported that among women deemed at high risk for VTE postpartum, 
640 as high as 4000 would require prophylaxis to prevent 1 episode of VTE [13].
The potential benefit of pharmacologic prophylaxis needs to be weighed against 
the potential for adverse outcomes associated with the intervention. The use of 
pharmacologic VTE prophylaxis after cesarean delivery has been associated with 
increased rates of wound morbidity. The number needed to harm (NNH) with the 
use of pharmacologic VTE prophylaxis after cesarean delivery has been reported 
to be as low as 200. Due to inadequate sample calculation in the available studies 
the optimal risk threshold for initiating pharmacological thromboprophylaxis 
in the antepartum and postpartum periods, particularly in women with lower-
risk thrombophilic traits and multiple (common) VTE risk factors remains to be 
established [16].
Another question is optimal optimal time to start and duration of thromboem-
bolism prophylaxis after a cesarean delivery. Recent guidelines have addressed the 
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Risk factors for VTE in hospitalization of pregnant women and puerperal women.
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prophylaxis to prevent the development of spinal or epidural hematomas take in con-
sideration the time of insert and removal of epidural catheter [5, 15, 16]. Prophylactic 
doses of enoxaparin (40 mg subcutaneously every day) may be started postopera-
tively as early as 4 hours after catheter removal but not earlier than 12 hours after the 
block was performed [4, 15, 17]. Another complication to be considered is iatrogenic 
postoperative bleeding. The risk of bleeding with prophylactic doses are usually mild, 
such as wound hematomas, and rarely life-threatening hemorrhagic complications 
[16–21]. In cases with significant intraoperative bleeding complications, the decision 
of when to start pharmacologic prophylaxis (if indicated) must be individualized 
according with the clinical and surgical scenarios [2, 3, 21].
Although the evidence is scarce Women with risk factors should receive throm-
boprophylaxis at minimum for 6 weeks postpartum; women with transient risk 
factors in the antepartum and intrapartum should receive thromboprophylaxis 
until hospital discharge or up to 2 weeks after delivery [2–5].
In SARS COVID-19 given the potential increase in VTE risk a weight-adjusted 
VTE prophylaxis with low molecular weight heparin (LMWH) should be consid-
ered in all pregnant and post partum women admitted to hospital (in the absence of 
active bleeding and with a platelet count above 30 × 109/L or indication for immedi-
ate delivery). In case of indicated or emergency delivery VTE prophylaxis should be 
evaluated individually [10, 11].
6. Pharmacologic agents for prophylaxis of VTE
The 2 most common agents used for prophylaxis of VTE are LMWH and 
Unfractionaded Heparin (UFH). Recent guidelines recommend LMWH (most 
recomended enoxaparin) as the first-line pharmacologic agent. Enoxaparin has 
a half-life of 4 to 6 hours and is eliminated by the kidney and it is not recom-
mended in patients with significant impaired renal function but has the advan-
tage of better bioavailability, longer half-life, more predictable anticoagulation 
effect, less bleeding risks, and less risk of heparin-induced thrombocytopenia 
and osteopenia [2–5, 17, 18].
The recommended dose of enoxaparin is typically 40 mg subcutaneously once 
a day. Obese women may require higher doses; some evidence supports the use of 
intermediate doses of enoxaparin (40 mg subcutaneously every 12 hours) for obese 
women or a weight-based prophylactic dose of 0.5 mg/kg subcutaneously every 
12 hours of enoxaparin in morbidly obese women after cesarean delivery [2, 17].
UFH has a shorter half-life than LMWH of 60 to 90 minutes and is mostly 
cleared by the reticuloendothelial system, rendering it a good choice in women 
with renal disease. Recommended prophylactic dosages in the postpartum period is 
5000 units subcutaneously every 8 to 12 hours [17].
Fondaparinux is a completely synthetic pentasaccharide heparin analog and 
the first of a new class of selective indirect antithrombin-dependent factor Xa 
inhibitors, which inhibits thrombin generation, has some benefit for thrombopro-
phylaxis. Heparin-induced thrombocytopenia (HIT) is an extremely rare situa-
tions of fondaparinux in comparison with the UFH and LMWH, suggesting that 
fondaparinux is an alternative for the treatment of thrombosis associated with HIT 
[22]. In a small study in Japan short term fondaparinux (2,5 mg/day)appears to be 
an adequate and safe method for prevention of symptomatic VTE in women at risk 
after cesarean section [22, 23].
There are insufficient safety and efficacy data to recommend the use of new oral 
anticoagulants (e.g., apixaban, rivaroxaban, dabigatran) during the postpartum 
period [24, 25].
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7. Contraindications and patient risks for pharmacological prophylaxis
a. Potential contraindications to prescribing enoxaparin or heparin.
Thrombocytopaenia - Low platelet count (<100.000 ui/ml)
High risk of uncontrolled hemorrhage or current bleeding
Adverse reaction/allergy to enoxaparin or heparin
Acute bacterial endocarditis [2]
b. Patient related risk factors for bleeding:
Current active major bleeding with need for transfusion
Current chronic bleeding over 48 hours
Bleeding disorders (e.g. hemophilia)
Recent central nervous system bleeding
Intracranial or spinal lesion
Current renal impairment with secondary coagulation did
Underlying coagulopathy or coagulation factor abnormalities
Thrombocytopaenia.- a platelet count <50000/uL
Severe platelet dysfunction
Active peptic ulcer or active ulcerative gastrointestinal disease
Obstructive jaundice or cholestasis
Recent major surgical procedure with a high bleeding risk [2, 3].
8. Summary of the recommendations
To date, guideline recommendations are mainly based on expert opinion rather 
than high-quality evidence and provide conflicting recommendations (Table 2).
Recently The Society of Maternal Fetal Medicine published a evidence based 
guideline summarized in Table 3 [17].
9.  Electronic medical records and improvements in the prevention  
of VTE
Predicting individual VTE risk is extremely challenging because no single vari-
able is strongly predictive, and we are investing on systems that incorporate mul-
tiple variables to produce significant predictive values for VTE. The medical records 
waistband Electronics (EMR) Scoring systems with use of artificial intelligence 
should be seen as an opportunity to support clinical decision. Some studies indicate 
that computer alert interventions may increase the adherence to appropriate risk 
stratification for VTE, reduce costs and avoiding unnecessary thromboprophylaxis 
in low-risk patients [15].
10. Conclusions
VTE remains an important and preventable cause of maternal morbidity 
and mortality during the postpartum period [26–29]. Despite absence or robust 
evidence use of mechanical prophylaxis sequential compression devices is an 
inexpensive, safe intervention and should be used in all women undergoing 
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cesarean delivery until the woman is fully ambulatory [1, 2, 4, 17]. The decision to 
add pharmacologic prophylaxis depends on the presence or absence of risk factors 
[2–4, 15, 17]. Women with a previous personal history of deep venous thrombosis 
or pulmonary embolism and women with a personal history of an inherited 
thrombophilia (either high-risk or low-risk), and should receive pharmacologic 
prophylaxis after cesarean delivery [3, 4, 27, 29]. Another risk factors like obesity 
Organization Recommendation Risk stratification
American College 
of Obstetricians and 
Gynecologists [4]
• Pneumatic compression for all
• Women with additional 
risk factors for VTE may 
benefit from pharmacologic 
prophylaxis
A risk scoring system is not endorsed
American College of 
Chest Physicians [3]
• Early mobilization is recom-
mended in absence of risk 
factors.
Prophylaxis with heparin is 
suggested when 1 major or 
2 or more minor risk factors 
are present or when 1 minor 
risk factor is associated with 
emergent cesarean section
In women at very high risk, we 
suggest ad pharmacologic to 
mechanical prophylaxis
After delivery, prophylaxis is 
suggested for up to 6 weeks 
postpartum in the presence of 
risk factors
Major risk factors for VTE:
Immobility(for at least 7 days antepartum)
Postpartum hemorrhage with surgical 
intervention
Previous history of VTE
Pregnancy induced hypertension with fetal 
growth restriction
Antithrombin deficiency
Factor V Leiden or Prothrombin gen 
mutations









Protein C or S deficiency
Royal College of 
Obstetricians and 
Gynecologists [2]
Women at high risk should 
receive pharmacologic 
prophylaxis for 6 weeks 
after delivery; women at 
intermediate risk for VTE 
should receive pharmacologic 
prophylaxis for at least 10 days 
after delivery.
For women at low risk for 
VTE, we recommender early 




any woman requiring antenatal LMWH, 
high-risk thrombophilia, low-risk 
thrombophilia with family history of 
thrombosis
Intermediate-risk Cesarean delivery 
after labor, Obesity, postpartum hospital 
readmission, surgical procedures during the 
puerperium, Maternal diseases - cancer, heart 
failure, active lupus, nephrotic syndrome, 
sickle cell disease, type 1 diabetes with 
nephropathy, inflammatory bowel disease,
or Two or more of the following: 
Age > 35 years, parity 3, obesity, smoker, 
elective cesarean delivery, family history 
of VTE, low-risk thrombophilia, varicose 
veins, current systemic infection, pregnancy 
induced hypertension, immobility, multiple 
pregnancy, preterm delivery, stillbirth, 




Current guidelines on prophylaxis of thromboembolism after C/S.
Current Topics in Caesarean Section
8
and clinical complications (Sickle cell disease, Hypertension, COVID 19 infec-
tions) should be considered. The use of universal or near-universal pharmaco-
logical prophylaxis for low risk women undergoing cesarean delivery, cannot be 
recommended until further studies demonstrate that such a strategy is beneficial 
[14]. At present, the available VTE risk stratification tools used to decide for or 
against pharmacologic prophylaxis have not been validated in women undergo-
ing cesarean delivery being a good opportunity for research and development. 
Individualization of care is recommended for women at very high risk for VfE 
and institucional safety bundles are recommended as a best practice [14, 15, 17]. 
In the last half-century, we have made tremendous progress in understanding the 
epidemiology and prevention of VTE, and it is imperative that these advances be 
studied and implemented in obstetric care [26].
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Recommendation Grade
1 All women who undergo cesarean sectionreceive sequential compression devices 
starting before surgery and that the compression devices be used continuously until 
discharge
1C
2 Women with a previous personal history of DVT venous thrombosis or PE submitted 
to cesarean section receive both mechanical and pharmacologic prophylaxis. 
Pharmacological must be maintained for up to 6 weeks postpartum
2C
3 Women with a personal history of an inherited thrombophilia (high-risk or low-risk) 
but no previous thrombosis submitted to cesarean section receive both mechanical and 
pharmacologic prophylaxis. Pharmacological must be maintained for up to 6 weeks 
postpartum
2C
4 Low-molecular-weight heparin is the preferred thromboprophylactic agent in 
pregnancy and the postpartum period
1C
5 We suggest the use of intermediate doses of enoxaparin in pharmacologic 
thromboprophylaxis for pregnant women with class III obesity,
2C
6 A patient safety bundle with an institutional protocol for venous thromboembolism 
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